6-溴-4-甲基-3,4-二氢-2H-1,4-苯并恶嗪 | 188947-79-7

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 6-溴-4-甲基-3,4-二氢-2H-1,4-苯并恶嗪
• 中文别名: 6-溴-4-甲基-3,4-二氢-2H-苯并[1,4]恶嗪
• 英文名称: 6-bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine
• 英文别名: 6-bromo-4-methyl-3,4-dihydro-2H-benzo[b] [1,4]oxazine；6-bromo-4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine；6-Bromo-4-methyl-2,3-dihydro-1,4-benzoxazine
• CAS: 188947-79-7
• 化学式: C₉H₁₀BrNO
• 分子量: 228.088
• InChiKey: FZYXJDPNHUFKLO-UHFFFAOYSA-N

物化性质

• 沸点：
  307.6±42.0 °C(Predicted)
• 密度：
  1.475±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

SDS

Name:	6-Bromo-4-methyl-3 4-dihydro-2H-1 4-benzoxazine Material Safety Data Sheet
Synonym:
CAS:	188947-79-7

Section 1 - Chemical Product MSDS Name:6-Bromo-4-methyl-3 4-dihydro-2H-1 4-benzoxazine Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
188947-79-7	6-Bromo-4-methyl-3,4-dihydro-2H-1,4-be		unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 188947-79-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H10BrNO
Molecular Weight: 228.09

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, reducing agents, amines.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 188947-79-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Bromo-4-methyl-3,4-dihydro-2H-1,4-benzoxazine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 188947-79-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 188947-79-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 188947-79-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-4-甲基-3,4-二氢-2H-1,4-苯并恶嗪 在 lithium aluminium tetrahydride 、 正丁基锂 、 叠氮磷酸二苯酯 、 potassium tert-butylate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 3.25h， 生成 (3aS,4R,8R,8aS)-5,7-Bis-(3-acetyl-benzyl)-2,2-dimethyl-4,8-bis-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethyl)-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one
  参考文献：
  名称：

  改进的基于环脲的HIV-1蛋白酶抑制剂的P1 / P1'取代基：合成，结构活性关系和X射线晶体结构分析。

  摘要：

  我们提出了几种新颖的P1 / P1'取代基，它们可以取代基于环脲的HIV蛋白酶抑制剂系列的特征性苄基P1 / P1'部分。与未取代的苄基类似物相比，这些取代基通常提供5-10倍的结合亲和力。最好的取代基是3，4-（亚乙二氧基）苄基。分子亲脂性的适当平衡促进了这种改善的结合亲和力向优良细胞抗病毒活性谱的转移。进一步评估了几种类似物的蛋白质结合和抗药性。根据化合物18的log P和溶解度曲线，选择其化合物18（IC90 = 8.7 nM）进行口服生物利用度研究。狗的10 mg / kg剂量具有适度的生物利用度，Cmax = 0.22 microg / mL。两种类似物的X射线晶体学分析揭示了3,4-（乙二氧基）苄基取代的类似物的效力的几个有趣特征：（1）比较这两种络合物，发现每个P1 / P1'取代基有两种不同的结合方式；（2）乙二氧基部分在Pro 81的3.6 A之内，可提供母体结构中缺少的更多范德华接触；（3）酶的Arg

  DOI：

  10.1021/jm960839i
• 作为产物：
  描述：

  4-溴-2-硝基苯酚 在 吡啶 、 盐酸 、 氢氧化钾 、 sodium hydroxide 、 甲基三辛基氯化铵 、 sodium cyanoborohydride 、 tin(ll) chloride 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 36.83h， 生成 6-溴-4-甲基-3,4-二氢-2H-1,4-苯并恶嗪
  参考文献：
  名称：

  改进的基于环脲的HIV-1蛋白酶抑制剂的P1 / P1'取代基：合成，结构活性关系和X射线晶体结构分析。

  摘要：

  我们提出了几种新颖的P1 / P1'取代基，它们可以取代基于环脲的HIV蛋白酶抑制剂系列的特征性苄基P1 / P1'部分。与未取代的苄基类似物相比，这些取代基通常提供5-10倍的结合亲和力。最好的取代基是3，4-（亚乙二氧基）苄基。分子亲脂性的适当平衡促进了这种改善的结合亲和力向优良细胞抗病毒活性谱的转移。进一步评估了几种类似物的蛋白质结合和抗药性。根据化合物18的log P和溶解度曲线，选择其化合物18（IC90 = 8.7 nM）进行口服生物利用度研究。狗的10 mg / kg剂量具有适度的生物利用度，Cmax = 0.22 microg / mL。两种类似物的X射线晶体学分析揭示了3,4-（乙二氧基）苄基取代的类似物的效力的几个有趣特征：（1）比较这两种络合物，发现每个P1 / P1'取代基有两种不同的结合方式；（2）乙二氧基部分在Pro 81的3.6 A之内，可提供母体结构中缺少的更多范德华接触；（3）酶的Arg

  DOI：

  10.1021/jm960839i

文献信息

• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047959A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量、空腹血糖升高、2型糖尿病、综合征X（也称为代谢综合征）及其相关疾病和并发症。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047961A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量，空腹血糖升高，2型糖尿病，综合征X（也称为代谢综合征）以及与之相关的疾病和并发症。
• 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES
  申请人：Andreini Matteo

  公开号：US20090209529A1

  公开（公告）日：2009-08-20

  The present invention relates to a compounds of formula I wherein R 1 , R 1′ , R 2 , R 3 , R 4 , X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及一种具有以下式I的化合物 其中R 1 ，R 1′ ，R 2 ，R 3 ，R 4 ，X，Ar和m如规范和索赔中定义，并且其药用活性酸盐。本发明的化合物具有Asp2（β-分泌酶，BACE 1或Memapsin-2）抑制活性，并且对于治疗由β-淀粉样蛋白水平升高或β-淀粉样蛋白沉积所特征的疾病，特别是阿尔茨海默病，是有用的。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047960A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量，空腹血糖升高，2型糖尿病，综合征X（也称为代谢综合征）以及与之相关的疾病和并发症。
• GLUTATHIONE-DETECTING FLUORESCENT PROBE
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US20170045525A1

  公开（公告）日：2017-02-16

  [Problem] To provide the following: a novel fluorescent probe for detecting a compound, such as glutathione, that contains a —SH group; a detection method using said fluorescent probe; and a detection kit containing said probe. [Solution] A fluorescent probe for detecting a compound containing an —SH group, wherein the fluorescent probe comprises a compound represented by formula (I) or a salt thereof (In the formula, X represents Si(Ra)(R b ), Ge(R a )(R b ), Sn(R a )(R b ), C(R a )(R b ), or O (wherein R a and R b each independently represent a hydrogen atom or alkyl group); R 1 represents a hydrogen atom, or 1-4 identical or different substituents independently selected from the group consisting of a cyano group, alkyl group, carboxyl group, ester group, alkoxy group, amide group, and azide group, each of which may be optionally substituted; R 2 represents a hydrogen atom, halogen atom, hydroxyl group, cyano group, or an alkyl group, alkynyl group, alkoxy group, aryl, or heteroaryl, each of which may be optionally substituted; R 3 and R 4 each independently represent a hydrogen atom or 1-3 identical or different substituents independently selected from the group consisting of a hydroxyl group, halogen atom, or an alkyl group, sulfo group, carboxyl group, ester group, amide group and azide group, each of which may be optionally substituted; R 5 , R 6 , R 7 and R 8 each independently represent a hydrogen atom or alkyl group, wherein, R 5 or R 6 , respectively together with R 3 , may form a ring structure including the nitrogen atoms bonded thereto, or R 7 or R 8 , respectively together with R 4 , may form a ring structure including the nitrogen atoms bonded thereto).

  提供以下内容：用于检测含有-SH基团的化合物（如谷胱甘肽）的新型荧光探针；使用所述荧光探针的检测方法；以及包含所述探针的检测试剂盒。解决方案：一种用于检测含有-SH基团的化合物的荧光探针，其中所述荧光探针包括由式（I）表示的化合物或其盐（在该式中，X表示Si（Ra）（Rb）、Ge（Ra）（Rb）、Sn（Ra）（Rb）、C（Ra）（Rb）或O（其中Ra和Rb各自独立地表示氢原子或烷基）；R1表示氢原子，或者独立选择自氰基、烷基、羧基、酯基、烷氧基、酰胺基和叠氮基的一致或不同的1-4个取代基，每个取代基可以选择性地被取代；R2表示氢原子、卤素原子、羟基、氰基或烷基、炔基、烷氧基、芳基或杂环芳基的一致或不同的取代基，每个取代基可以选择性地被取代；R3和R4各自独立地表示氢原子或独立选择自羟基、卤素原子或烷基、磺酰基、羧基、酯基、酰胺基和叠氮基的一致或不同的1-3个取代基，每个取代基可以选择性地被取代；R5、R6、R7和R8各自独立地表示氢原子或烷基，其中，R5或R6，分别与R3一起，可以形成包括与其相结合的氮原子的环结构，或者R7或R8，分别与R4一起，可以形成包括与其相结合的氮原子的环结构）。